Objective To investigate the effect of the decoction on treating Helicobacter pylori (Hp) positive gastric ulcer and its effect on gastrointestinal hormones and gastric mucosa morphology. Methods This prospective study selected 72 patients with Hp-positive gastric ulcers of the Piwei damp-heat syndrome type who were treated at our hospital between October 2021 and September 2022. The patients were randomly divided into an experimental group and a control group, with 36 cases in each group. The control group received conventional quadruple therapy, while the experimental group received Baiji Yulian Decoction in addition to the quadruple therapy for 6 weeks. Efficacy was evaluated based on gastrointestinal hormone levels, gastric mucosal morphology, Hp eradication rate, and TCM symptom scores. Results Before treatment, gastrointestinal hormone levels, gastric mucosal morphology and traditional chinese medicine syndrome (TCM) points were compared between the two groups. After treatment, the GAS and VIP levels in the two groups were lower than before treatment, and the difference was statistically significant, the control group, the MTL level was higher than the patients before treatment, the difference was statistically significant, and the test group was higher than the control group, the difference was statistically significant. The gland density, mucosal thickness and degree of inflammatory cell infiltration were lower than those before treatment, and the difference was statistically significant, and the difference was lower in the test group than in the control group. Two groups of patients with epigastric burning pain, dry mouth and chest, acid reflux, irritability, constipation, new abdominal distension, acid reflux, nausea, stool, and tongue pulse of TCM syndrome points are lower than before treatment, difference has statistical significance, the test group is lower than the control group, difference have statistical difference. The eradication rate and total response rate of Helicobacter pylori in the test group were significantly higher than that in the control group, and the difference was significant. Conclusion The combination of white and quadruple therapy can significantly improve the Hp eradication rate of Hp positive gastric ulcer patients, improve gastric mucosa morphology, and regulate gastrointestinal hormone levels through multiple targets, with remarkable clinical efficacy.
Key words
Hp positive gastric ulcer /
dampness and heat of spleen and stomach /
white and officinalis officinalis soup /
integrated Chinese and western medicine
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] GAO N, YAN S, CHEN B.Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer[J]. Altern Ther Health Med, 2023, 29(2): 213-217.
[2] PAN Y, JIAO F Y.Helicobacter pylori infection and gastric microbiota: Insights into gastric and duodenal ulcer development[J]. World J Gastroenterol, 2025, 31(7): 100044.
[3] YUCEL O.Interactions between Helicobacter pylori and gastroesophageal reflux disease[J]. Esophagus, 2019, 16(1): 52-62.
[4] JIN L X, FANG Y P, XIA C M, et al.Helicobacter pylori infection alters gastric microbiota structure and biological functions in patients with gastric ulcer or duodenal ulcer[J]. World J Gastroenterol, 2024, 30(24): 3076-3085.
[5] 赵静, 斯望春, 王佩珠, 等. 幽门螺杆菌阳性胃溃疡患者T淋巴细胞及相关炎症因子水平[J]. 中华医院感染学杂志, 2022, 32(07): 1014-1017.
[6] 姬志鸿, 李凤敏, 吴振伟. 荜铃胃痛颗粒联合改良四联疗法治疗Hp阳性胃溃疡的临床研究[J]. 实用中西医结合临床, 2022, 22(13): 22-25.
[7] MOUSAVI T, NIKFAR S, ABDOLLAHI M.The pharmacotherapeutic management of duodenal and gastric ulcers[J]. Expert Opin Pharmacother, 2022, 23(1): 63-89.
[8] 周少林, 管寿明, 徐鑫. 自拟温中愈溃汤联合西医常规治疗Hp阳性胃溃疡患者的临床观察[J]. 中国中医药科技, 2022, 29(05): 867-869.
[9] 王芳, 秦燕鸿, 王婧. 芪连清胃方辅助治疗幽门螺杆菌阳性胃溃疡的疗效观察[J]. 世界中西医结合杂志, 2022, 17(09): 1854-1858.
[10] 王蓓蓓, 白梅. 黄芪建中汤加减联合四联疗法对Hp阳性胃溃疡患者Hp清除率及复发率的影响[J]. 医学信息, 2022, 35(20): 145-147.
[11] 中华医学会, 中华医学会杂志社, 中华医学会消化病学分会, 等. 消化性溃疡基层诊疗指南 (2023年)[J]. 中华全科医师杂志, 2023, 22(11): 1108-1117.
[12] 中华中医药学会脾胃病分会, 李玉锋, 王垂杰, 等. 消化性溃疡中医诊疗专家共识 (2023)[J]. 中医杂志, 2024, 65(10): 1086-1092.
[13] 李群, 熊首先, 胡定政, 等. 疏肝清胃汤结合四联疗法治疗Hp阳性胃溃疡的临床疗效及对Hp清除、炎症因子水平的影响研究[J]. 四川中医, 2023, 41(03): 79-81.
[14] 高炜, 徐艳霞, 刘圆圆, 等. 小檗碱调控核因子κB信号转导通路对幽门螺杆菌感染人胃癌细胞的影响[J]. 世界中医药, 2022, 17(12): 1708-1711.
[15] 朱晓彤, 曾梅艳, 宋厚盼, 等. 基于关键基因与核心microRNA探讨大黄-黄连药对抗Hp感染的分子机制[J]. 中国中西医结合消化杂志, 2021, 29(01): 36-44.
[16] 何燕珊, 刘奇越, 邓雅方, 等. 多糖对胃溃疡作用机制研究现状[J]. 中国临床药理学杂志, 2021, 37(10): 1251-1254.
[17] 赖燕婷, 邓依晴, 张冉, 等. 基于网络药理学和分子对接探究中药复方防治幽门螺杆菌感染的作用机制[J]. 中国老年学杂志, 2024, 44(19): 4656-4660.
[18] 王红妹, 吴元祥, 刘建, 等. 三七白及散联合四联疗法对血瘀型十二指肠溃疡的疗效及影响Hp根除的因素分析[J]. 世界中西医结合杂志, 2022, 17(09): 1872-1876.
[19] 李莉, 杨伟, 梁春耕, 等. 吴茱萸碱调控EGFR/MAPK/ERK通路对Hp诱导慢性萎缩性胃炎大鼠的作用机制[J]. 河北医学, 2025, 31(02): 215-223.
[20] 邹紫荆, 张军林. 药食同源中药天然产物抗幽门螺杆菌研究进展[J]. 鄂州大学学报, 2024, 31(04): 109-112.
[21] 王国平, 韩秀敏, 王学典, 等. 瑞巴派特联合艾司奥美拉唑四联疗法对Hp阳性胃溃疡患者胃黏膜形态及胃肠激素的影响[J]. 反射疗法与康复医学, 2024, 5(13): 161-163.
[22] 宋利华, 左罗, 黄美云, 等. 艾司奥美拉唑四联疗法联合双歧杆菌三联活菌对幽门螺杆菌阳性胃溃疡的疗效[J]. 郑州大学学报 (医学版), 2024, 59(03): 390-394.
[23] 沈佳仪, 单君康, 吉如意. 虚寒胃痛颗粒联合西药治疗老年幽门螺杆菌阳性胃溃疡临床研究[J]. 新中医, 2024, 56(05): 81-85.
[24] 李九清, 宋翔, 李亚如. 瑞巴派特改良四联疗法对幽门螺杆菌阳性胃溃疡患者胃溃疡愈合、胃肠激素及PG水平的影响[J]. 航空航天医学杂志, 2024, 35(05): 573-575.
[25] 马娟, 刘文楷, 陈娜, 等. 荜铃胃痛颗粒联合四联疗法治疗幽门螺杆菌阳性胃溃疡疗效及对胃肠道激素、T淋巴细胞亚群的影响[J]. 现代中西医结合杂志, 2024, 33(11): 1571-1575.
[26] 迟笑倩, 柴常伟, 张海婧, 等. 黄连碱衍生物Q3通过调节TLR4/NF-κB信号通路和肠道微生物改善葡聚糖硫酸钠诱导的小鼠溃疡性结肠炎研究[J]. 中国药学杂志, 2024, 59(17): 1581-1589.
[27] 徐燕, 张平英, 陈静, 等. 探讨延胡索乙素调控miR-22介导NLRP3/Caspase-1/GSDMD细胞焦亡通路对老年急性胃炎大鼠炎症及胃黏膜的影响[J]. 中国老年学杂志, 2024, 44(20): 5031-5035.
[28] 李玉锋, 王垂杰. 《消化性溃疡中医诊疗专家共识 (2023) 》解读[J]. 中国中西医结合消化杂志, 2024, 32(6): 507-510.
[29] 侯欣, 宋红, 沈琰, 等. 柴黄胃溃宁对肝郁脾虚证胃溃疡大鼠肠道菌群的影响[J]. 中华中医药杂志, 2023, 38(10): 4924-4929.
[30] 厉佳辉, 刘晓谷, 金佳美, 等. 痛泻要方对肝郁脾虚型胃溃疡大鼠肠道菌群的影响[J]. 时珍国医国药, 2024, 35(11): 2587-2592.
PDF(1753 KB)
